Uniunea Europeană - malteză - EMA (European Medicines Agency)

h. lundbeck a/s - vortioxetine - disturb depressiv, maġġur - psychoanaleptics, - trattament ta 'episodji depressivi maġġuri fl-adulti.

Uniunea Europeană - malteză - EMA (European Medicines Agency)

novartis europharm limited - valsartan, amlodipine (as amlodipine besilate) - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - trattament ta 'ipertensjoni essenzjali. copalia huwa indikat f'pazjenti li l-pressjoni tad-demm mhijiex ikkontrollata adegwatament bl-amlodipina jew valsartan monoterapija.

Uniunea Europeană - malteză - EMA (European Medicines Agency)

novartis europharm limited - l-amlodipina, valsartan - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - trattament ta 'ipertensjoni essenzjali. dafiro huwa indikat f'pazjenti li l-pressjoni tad-demm mhijiex ikkontrollata adegwatament bl-amlodipina jew valsartan monoterapija.

Uniunea Europeană - malteză - EMA (European Medicines Agency)

pfizer europe ma eeig - parecoxib sodium - uġigħ, wara l-operazzjoni - coxibs, antiinflammatory and antirheumatic products - għat-trattament għal żmien qasir ta 'uġigħ wara l-operazzjoni fl-adulti.

Uniunea Europeană - malteză - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - insuffiċjenza tal-qalb - antagonisti ta ' angiotensin ii, kombinazzjonijiet oħra, aġenti li jaġixxu fuq is-sistema renin-angiotensin - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

Uniunea Europeană - malteză - EMA (European Medicines Agency)

novartis europharm limited - valsartan, amlodipine (as amlodipine besilate) - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - trattament ta 'ipertensjoni essenzjali. exforge huwa indikat f'pazjenti li l-pressjoni tad-demm mhijiex ikkontrollata adegwatament bl-amlodipina jew valsartan monoterapija.

Uniunea Europeană - malteză - EMA (European Medicines Agency)

novartis europharm ltd - valsartan, amlodipine (as amlodipine besilate) - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - trattament ta 'ipertensjoni essenzjali. imprida huwa indikat f'pazjenti li l-pressjoni tad-demm mhijiex ikkontrollata adegwatament bl-amlodipina jew valsartan monoterapija.

Uniunea Europeană - malteză - EMA (European Medicines Agency)

janssen-cilag international nv - canagliflozin - diabetes mellitus, tip 2 - drogi użati fid-dijabete - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 u 5.

Uniunea Europeană - malteză - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - insuffiċjenza tal-qalb - aġenti li jaġixxu fuq is-sistema renin-angiotensin - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.

Uniunea Europeană - malteză - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulina glargine - diabetes mellitus - drogi użati fid-dijabete - it-trattament tad-dijabete mellitus fl-adulti, l-adoloxxenti u t-tfal mill-età ta ' 6 snin.